MetLife Investment Management
IMRX icon

MetLife Investment Management’s Immuneering IMRX Stock Holding History

MetLife Investment Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$167K Buy
+33,479
New +$169K ﹤0.01% 2514
2024
Q1 		– Sell
-11,257
Closed -$82.7K – 2800
2023
Q4 		$82.7K Hold
11,257
– – ﹤0.01% 2682
2023
Q3 		$86.5K Hold
11,257
– – ﹤0.01% 2650
2023
Q2 		$114K Buy
+11,257
New +$108K ﹤0.01% 2596
2021
Q4 		– Sell
-3,719
Closed -$98.7K – 2524
2021
Q3 		$98.7K Buy
+3,719
New +$99.9K ﹤0.01% 2443

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

MetLife Investment Management's IMRX Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Immuneering (IMRX) in Q2 2026: 33,479 shares worth $167K. The stake represents ﹤0.01% of the portfolio and ranks #2514 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in IMRX as recently as Q4 2023.

MetLife Investment Management first reported a position in IMRX in Q3 2021 and has held it in 5 quarters since. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • MetLife Investment Management held 33,479 shares of Immuneering worth $167K as of Q2 2026.
  • Immuneering was a new MetLife Investment Management position in Q2 2026.
  • Immuneering made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2514 holding.
  • MetLife Investment Management first reported a position in Immuneering in Q3 2021 and has held it in 5 quarters since.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.